Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) monotherapy is a standard of care for patients with recurrent or metastatic non‐small cell lung cancers (NSCLC) that harbor EGFR mutations, such as exon 19 deletion and L858R point mutation.1 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.